Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

NCT01234337 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

537

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Sorafenib (Nexavar, BAY43-9006)
DRUG: Placebo
DRUG: Capecitabine

Sponsor

Bayer

Collaborators

[object Object]